Interpreting JC Virus Test Results in Multiple Sclerosis Management: Are You Up to Speed?

Update: 2025-10-31

Description

What do expert recommendations say about John Cunningham (JC) virus testing when switching to a biosimilar?

Credit available for this activity expires: 10/31/2026
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/interpreting-jc-virus-test-results-multiple-sclerosis-2025a1000qzm?ecd=bdc_podcast_libsyn_mscpedu

Comments

In Channel

Advances in the Pharmacologic Management of Obesity: An Expert Digest of the Latest Data

2025-11-2716:01

Breaking the Silence: Tackling Liver Fibrosis in MASH: Who to Treat With Novel Therapies

2025-11-2518:45

Coexisting Comorbidities: Advancing Holistic Care in COPD

2025-11-2433:50

Novel Biological Approaches for Enhanced Obesity and Diabetes Management – What's Next?

2025-11-2439:10

Latest Advances in mHSPC: An Update From Berlin 2025

2025-11-2020:06

Conference Insights: Breaking Developments in ALK-Positive NSCLC and ES-SCLC

2025-11-2035:03

Charting the Course for Metastatic Breast Cancer Care: Optimizing First-Line Treatment and Beyond

2025-11-1701:17:23

Paving the Way for Success in Integrating Biosimilars Into Multiple Sclerosis Care: Optimizing Communication

2025-11-1737:33

Advancing Personalized Care for Prostate Cancer: Patient-Centered Solutions for mHSPC and nmCRPC

2025-11-1301:19:22

Reshaping Obesity and Diabetes Care With Innovative Multiagonism Concepts

2025-11-1226:39

The Hidden Battle: Understanding Chronic Inflammation in Aging People Living With HIV and Comorbidities